These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9675959)

  • 21. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial.
    McMurray J; Køber L; Robertson M; Dargie H; Colucci W; Lopez-Sendon J; Remme W; Sharpe DN; Ford I
    J Am Coll Cardiol; 2005 Feb; 45(4):525-30. PubMed ID: 15708698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
    Lancet; 1997 Feb; 349(9049):375-80. PubMed ID: 9033462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy.
    Jovanovic D; Jovovic D; Mihailovic-Stanojevic N; Miloradovic Z; Naumovic R; Dimitrijevic J; Maksic N; Djukanovic L
    Biomed Pharmacother; 2009 Sep; 63(8):571-6. PubMed ID: 19013753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study.
    Galzerano D; Tammaro P; del Viscovo L; Lama D; Galzerano A; Breglio R; Tuccillo B; Paolisso G; Capogrosso P
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1563-9. PubMed ID: 16364826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of left ventricular function with carvedilol before high-risk cardiac surgery.
    Kotlyar E; Macdonald PS; Keogh AM; Arnold RH; McCaffrey DJ; Wilson MK; Spratt PM
    J Heart Lung Transplant; 2001 Oct; 20(10):1129-31. PubMed ID: 11595569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms and Treatment of Intradialytic Hypertension.
    Van Buren PN; Inrig JK
    Blood Purif; 2016; 41(1-3):188-93. PubMed ID: 26765312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients.
    Marazzi G; Volterrani M; Caminiti G; Iaia L; Massaro R; Vitale C; Sposato B; Mercuro G; Rosano G
    J Card Fail; 2011 Sep; 17(9):703-9. PubMed ID: 21872138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy.
    Tatli E; Kurum T
    Can J Cardiol; 2005 Mar; 21(4):344-8. PubMed ID: 15838561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interdialytic ambulatory blood pressure in patients with intradialytic hypertension.
    Van Buren PN; Toto R; Inrig JK
    Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):15-23. PubMed ID: 22123207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of salt intake on the antihypertensive effect of carvedilol.
    Ruilope LM; Lahera V
    J Hypertens Suppl; 1993 Jun; 11(4):S17-9. PubMed ID: 8104238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The effects of mid- and long-term administration (3-4 years) of carvedilol in patients with idiopathic dilated cardiomyopathy].
    Metra M; Nodari S; Garbellini M; Boldi E; Rosselli F; Milan E; Giubbini R; Dei Cas L
    Cardiologia; 1997 May; 42(5):503-12. PubMed ID: 9289367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients.
    Galzerano D; Di Michele S; Paolisso G; Tuccillo B; Lama D; Carbotta S; Cittadini A; Tedesco MA; Gaudio C
    J Renin Angiotensin Aldosterone Syst; 2012 Dec; 13(4):496-503. PubMed ID: 22546623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood pressure and the risk of complex arrhythmia in renal insufficiency, hemodialysis, and renal transplant patients.
    de Lima JJ; Vieira ML; Lopes HF; Gruppi CJ; Medeiros CJ; Ianhez LE; Krieger EM
    Am J Hypertens; 1999 Feb; 12(2 Pt 1):204-8. PubMed ID: 10090349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of additional low-dose carvedilol in maintenance hemodialysis patients with asymptomatic left ventricular systolic dysfunction].
    Nakayama M; Ishii A; Takeguchi F; Nakano H
    J Cardiol; 2006 Jun; 47(6):285-91. PubMed ID: 16800371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol.
    Khattar RS; Senior R; Soman P; van der Does R; Lahiri A
    Am Heart J; 2001 Oct; 142(4):704-13. PubMed ID: 11579363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
    McTavish D; Campoli-Richards D; Sorkin EM
    Drugs; 1993 Feb; 45(2):232-58. PubMed ID: 7681374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection.
    Feuerstein GZ; Ruffolo RR
    Eur Heart J; 1995 Jul; 16 Suppl F():38-42. PubMed ID: 8521883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure.
    Del Sindaco D; Pulignano G; Cioffi G; Tarantini L; Di Lenarda A; De Feo S; Opasich C; Minardi G; Giovannini E; Leggio F
    J Cardiovasc Med (Hagerstown); 2007 Sep; 8(9):675-82. PubMed ID: 17700396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Left ventricular hypertrophy regression during antihypertensive treatment.
    Eichstaedt H; Danne O; Schroeder RJ; Kreuz D
    Clin Investig; 1992; 70 Suppl 1():S79-86. PubMed ID: 1350490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.